Find News

Filter articles

Applied Filters

Showing 951 to 960 of 1033 results

Eli Lilly targets more than 30 generics in Effient patent case

US17-03-2014Legal developments

Eli Lilly has filed suit against more than 30 generic drug makers at the US District Court for the Southern District of Indiana for allegedly infringing three patents related to platelet inhibitor drug Effient (prasugrel).

Generics circle as Virginia court invalidates Celebrex patent

US13-03-2014Legal developments

The US District Court for the Eastern District of Virginia has invalidated one of Pfizer’s patents covering blockbuster arthritis drug Celebrex.

Life Sciences Law Forum: UPC: “So much more to be done”


While the political will exists for the introduction of the Unified Patent Court next year, much more still needs to be done, according to Adam Cooke, a partner in DLA Piper's IP and technology group.

Indian court dismisses Teva’s bid to block Copaxone generic


The Delhi High Court has dismissed Teva’s action to stop Hyderabad-based Natco Pharma from marketing a generic version of its blockbuster multiple sclerosis drug Copaxone (glatiramer acetate).

Federal Circuit rejects challenge to GSK’s Avodart and Jalyn

US28-02-2014Legal developments

The US Appeals Court for the Federal Circuit has affirmed a lower court decision that GlaxoSmithKline’s patent covering Avodart and Jalyn is valid, rejecting claims put forward by a group of generic drug makers.

US district court invalidates Megace patent

Taiwan, US25-02-2014Legal developments

The US District Court for the District of Maryland has ruled that Taiwanese company TWi Pharmaceuticals’ generic version of Par Pharmaceuticals’ Megace ES drug does not infringe US patent 7,101,576.

Pfizer Australia faces antitrust accusations


Australia’s antitrust regulator has launched proceedings against Pfizer’s Australian arm, accusing it of abusing its power when supplying cholesterol-lowering drug atorvastatin to pharmacies.

Appeals court ruling blocks Lyrica competition until 2018


The US Court of Appeals for the Federal Circuit has upheld a patent covering Pfizer’s pain drug Lyrica, closing the market to any generic challengers until 2018.

Generic KRKA to receive damages in Nexium case

UK28-01-2014Legal developments

The UK High Court has decided to award Slovenian generic pharmaceutical company KRKA damages after a preliminary injunction enforced against the company by AstraZeneca was discharged.

India considers more compulsory licences


A government-appointed panel in India is preparing to evaluate more patented drugs for local generic pharmaceutical companies to mimic, according to reports.

Showing 951 to 960 of 1033 results